Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HIV-1 infected on HAART regimen containing 2 NRTI and boosted PI for at least 12 weeks prior to screening. Subjects may not have experienced virological failure to more than one prior PI-containing regimen. Must be able to swallow tablets
Viral load \<400 c/mL at screening and stable for at least 6 months
Signs of fat redistribution and lipohypertrophy (abdominal) Waist to Hip Ratio \>0.90 and Waist Circumference \>88.2 cm for men and Waist Circumference \>75.3 for women
You may not be if
Pregnant or breastfeeding women
New HIV-related opportunistic infections
Active alcohol or substance use
Grade 4 lab toxicity
History of taking atazanavir (ATV)
Prohibited therapies, including non-nucleoside reverse transcriptase inhibitors (NNRTI)
Clareo Health | Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
